Filya Zhebrovska, Chair of the Supervisory Board of Farmak, has been ranked among the top 20 Ukrainians who invested the most in Ukraine during the full-scale war, according to a ranking by LIGA.net and the Federation of Employers of Ukraine.
The ranking covers the period from 2022 to 2025 and honors Ukrainian business representatives who, despite wartime risks, have continued investing in enterprise development and large-scale projects within the country, based on data provided by the companies regarding capital investments.
Throughout the full-scale war, Farmak has continued investing in production development, digitalization, and innovation. One of the largest projects was the transition to the modern SAP S/4HANA ERP system, which integrated the company’s key business processes and laid the foundation for further digital transformation.
The company also directs investments toward modernizing research laboratories, re-equipping production facilities, and developing modern warehouse infrastructure. Among Farmak’s strategic projects is the construction of a new center in Kyiv designed to strengthen the company’s R&D potential and the development of modern medicines. The total amount of capital investments for the 2022–2025 period reached 3.6 billion UAH.
Other participants in the ranking include Rinat Akhmetov (DTEK), Yuriy Kosiuk (MHP), Vitaliy Antonov (OKKO), and others.
You can find more details about the ranking in the LIGA.net special project via the link.
Farmak Group is a global pharmaceutical business founded in Ukraine in 1925, with production facilities in Ukraine and Spain, as well as companies and international representative offices in Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Mexico, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova. Today, the company’s portfolio includes over 450 names of medicinal products and exports products to more than 60 countries worldwide.
